Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab with Gemcitabine, Nab-Paclitaxel, and Hydroxychloroquine in Pancreatic Cancer
NCT03344172Phase 2Terminated
- Start
- Dec 2017
- Primary completion
- Apr 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab in pancreatic adenocarcinoma (PDAC). Started Dec 2017; status: terminated.
02
Drugs
avelumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03344172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03344172.